SCHOENBACH and his co-workers first reported the successful treatment of North American blastomycosis with stilbamidine in 1951.1 Prior to that time experiences with the toxic effects of stilbamidine had been well documented.* In 1948, Snapper described the effect of 2-hydroxystilbamidine on the course of multiple myeloma. Of particular interest was the lessened toxicity of the 2-hydroxy form of the drug.7 Snapper and others,† in later work, confirmed this decreased toxicity and later reported the effectiveness of this form of stilbamidine in the treatment of blastomycosis.10 We would like to add another case of systemic blastomycosis with apparent cure following intensive treatment with 2-hydroxystilbamidine.
REPORT OF A CASE
R. D. M., a 41-year-old white locomotive engineer, was admitted to the dermatologic and medical service at Michael Reese Hospital on April 8, 1953, with a known diagnosis of disseminated blastomycosis. The past history revealed that in 1927 he had
WEINBERG BJ, LAWRENCE CH, BUCHHOLZ A. SYSTEMIC BLASTOMYCOSIS TREATED WITH 2-HYDROXYSTILBAMIDINE. AMA Arch Intern Med. 1954;94(3):493-496. doi:10.1001/archinte.1954.00250030163020